Search results

14 results for Omalizumab

Sorted by Relevance . Sort by Date

  1. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

  2. Skin conditions

    Everything NICE has said on managing skin conditions and skin damage in an interactive flowchart

  3. Past appeals and decisions

    TA ID Appraisal Short title TA201 Asthma (in children) - omalizumab TA265 Bone metastases from solid tumours - denosumab TA566

  4. Asthma

    Everything NICE has said on diagnosing, monitoring and managing asthma in children, young people and adults in an interactive flowchart

  5. Technology appraisal block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.